Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 406 word(s) 406 2020-12-15 07:42:39

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Ren, B. ABCG2 Gene. Encyclopedia. Available online: (accessed on 18 June 2024).
Ren B. ABCG2 Gene. Encyclopedia. Available at: Accessed June 18, 2024.
Ren, Bruce. "ABCG2 Gene" Encyclopedia, (accessed June 18, 2024).
Ren, B. (2020, December 24). ABCG2 Gene. In Encyclopedia.
Ren, Bruce. "ABCG2 Gene." Encyclopedia. Web. 24 December, 2020.
ABCG2 Gene

ATP binding cassette subfamily G member 2 (Junior blood group)


1. Normal Function

The ABCG2 gene belongs to a group of genes called the ATP-binding cassette family; genes in this family provide instructions for making proteins that transport molecules across cell membranes. In the intestines, the ABCG2 protein helps release (secrete) a substance called urate into the urine. Urate is a byproduct of certain normal biochemical reactions in the body. In the bloodstream it acts as an antioxidant, protecting cells from the damaging effects of unstable molecules called free radicals. Urate levels are regulated by the kidneys and, to a lesser extent, by the intestines.

The ABCG2 protein also transports certain drugs out of cells. For example, this protein clears some chemotherapy drugs from organs and tissues. Transport of these drugs allows them to have their intended effects and be eliminated from the body.

2. Health Conditions Related to Genetic Changes

2.1 Gout

Genetic changes in the ABCG2 gene have been found to be associated with a condition called gout, which is a form of arthritis that causes painful join inflammation.

ABCG2 gene changes associated with gout decrease the protein's ability to release urate. One variant replaces the protein building block (amino acid) glutamine with the amino acid lysine at position 141 in the protein (written as Gln141Lys or Q141K). This change reduces the protein's ability to secrete urate by half. Another variant creates a premature stop signal in the instructions for making the ABCG2 protein (written as Gln126Ter or Q126X), which results in no functional ABCG2 protein. Variants in the ABCG2 gene reduce the removal of urate in the blood, which causes the blood level of urate to rise. The excess urate can accumulate in the body's joints in the form of crystals, triggering an inflammatory response from the immune system and leading to gout.

While changes in the ABCG2 gene can alter urate levels in the body, they are not enough to cause gout by themselves. A combination of dietary, genetic, and other environmental factors play a part in determining the risk of developing this complex disorder.

2.2 Other Names for This Gene

  • ABC15
  • ABCP
  • ATP-binding cassette transporter G2
  • ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)
  • BCRP
  • BCRP1
  • BMDP
  • breast cancer resistance protein
  • CD338
  • CDw338
  • EST157481
  • mitoxantrone resistance-associated protein
  • MRX
  • multi drug resistance efflux transport ATP-binding cassette sub-family G (WHITE) member 2
  • MXR
  • MXR-1
  • MXR1
  • placenta specific MDR protein
  • placenta-specific ATP-binding cassette transporter
  • UAQTL1


  1. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, PistisG, Ruggiero D, O'Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RP, Brown MJ, Gaffo AL, Pirastu N, LiG, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, LiuX, Malerba G, Lopez LM, van der Harst P, Li X, Kleber ME, Hicks AA, Nolte IM,Johansson A, Murgia F, Wild SH, Bakker SJ, Peden JF, Dehghan A, Steri M, TenesaA, Lagou V, Salo P, Mangino M, Rose LM, Lehtimäki T, Woodward OM, Okada Y, Tin A,Müller C, Oldmeadow C, Putku M, Czamara D, Kraft P, Frogheri L, Thun GA,Grotevendt A, Gislason GK, Harris TB, Launer LJ, McArdle P, Shuldiner AR,Boerwinkle E, Coresh J, Schmidt H, Schallert M, Martin NG, Montgomery GW, Kubo M,Nakamura Y, Tanaka T, Munroe PB, Samani NJ, Jacobs DR Jr, Liu K, D'Adamo P, UliviS, Rotter JI, Psaty BM, Vollenweider P, Waeber G, Campbell S, Devuyst O, Navarro P, Kolcic I, Hastie N, Balkau B, Froguel P, Esko T, Salumets A, Khaw KT,Langenberg C, Wareham NJ, Isaacs A, Kraja A, Zhang Q, Wild PS, Scott RJ, HollidayEG, Org E, Viigimaa M, Bandinelli S, Metter JE, Lupo A, Trabetti E, Sorice R,Döring A, Lattka E, Strauch K, Theis F, Waldenberger M, Wichmann HE, Davies G,Gow AJ, Bruinenberg M; LifeLines Cohort Study, Stolk RP, Kooner JS, Zhang W,Winkelmann BR, Boehm BO, Lucae S, Penninx BW, Smit JH, Curhan G, Mudgal P, PlengeRM, Portas L, Persico I, Kirin M, Wilson JF, Mateo Leach I, van Gilst WH, Goel A,Ongen H, Hofman A, Rivadeneira F, Uitterlinden AG, Imboden M, von Eckardstein A, Cucca F, Nagaraja R, Piras MG, Nauck M, Schurmann C, Budde K, Ernst F, FarringtonSM, Theodoratou E, Prokopenko I, Stumvoll M, Jula A, Perola M, Salomaa V, ShinSY, Spector TD, Sala C, Ridker PM, Kähönen M, Viikari J, Hengstenberg C, NelsonCP; CARDIoGRAM Consortium; DIAGRAM Consortium; ICBP Consortium; MAGIC Consortium,Meschia JF, Nalls MA, Sharma P, Singleton AB, Kamatani N, Zeller T, Burnier M,Attia J, Laan M, Klopp N, Hillege HL, Kloiber S, Choi H, Pirastu M, Tore S,Probst-Hensch NM, Völzke H, Gudnason V, Parsa A, Schmidt R, Whitfield JB, FornageM, Gasparini P, Siscovick DS, Polašek O, Campbell H, Rudan I, Bouatia-Naji N,Metspalu A, Loos RJ, van Duijn CM, Borecki IB, Ferrucci L, Gambaro G, Deary IJ,Wolffenbuttel BH, Chambers JC, März W, Pramstaller PP, Snieder H, Gyllensten U,Wright AF, Navis G, Watkins H, Witteman JC, Sanna S, Schipf S, Dunlop MG, Tönjes A, Ripatti S, Soranzo N, Toniolo D, Chasman DI, Raitakari O, Kao WH, Ciullo M,Fox CS, Caulfield M, Bochud M, Gieger C. Genome-wide association analysesidentify 18 new loci associated with serum urate concentrations. Nat Genet. 2013 Feb;45(2):145-54. doi: 10.1038/ng.2500.
  2. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Takada Y, Okada C,Sakurai Y, Hosoya T, Kanai Y, Suzuki H, Shinomiya N. Identification of ABCG2dysfunction as a major factor contributing to gout. Nucleosides NucleotidesNucleic Acids. 2011 Dec;30(12):1098-104. doi: 10.1080/15257770.2011.627902.
  3. Matsuo H, Takada T, Nakayama A, Shimizu T, Sakiyama M, Shimizu S, Chiba T,Nakashima H, Nakamura T, Takada Y, Sakurai Y, Hosoya T, Shinomiya N, Ichida K.ABCG2 dysfunction increases the risk of renal overload hyperuricemia. NucleosidesNucleotides Nucleic Acids. 2014;33(4-6):266-74. doi:10.1080/15257770.2013.866679.
  4. Merriman T. Genomic Influences on Hyperuricemia and Gout. Rheum Dis Clin NorthAm. 2017 Aug;43(3):389-399. doi: 10.1016/j.rdc.2017.04.004. Review.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 470
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 24 Dec 2020
Video Production Service